Latest updates and announcements from Emmes Group

Mesoblast and BMT CTN to initiate pivotal trial of Ryoncil®

Dr John Levine, Chair of the BMT CTN Steering Committee and Professor of Internal Medicine and Pediatrics, Icahn School of Medicine at Mount Sinai, New York said: “We are delighted to be partnering with Mesoblast in this pivotal Phase 3…

Rockville-Based CRO Emmes Groups’ OptymEdge launch the first dedicated ophthalmology clinical trial platform at ARVO

OptymEdge has long-standing expertise in visual function endpoints and certification and is leveraging this experience to reimagine and streamline processes across complex ophthalmology trials.

Emmes Group Earns ISO 27001:2022 Certification for Data Security

The commendation from the International Organization for Standardization (ISO) underscores Emmes Group’s dedication to delivering secure, innovative, and data-driven solutions to its biotech and pharmaceutical partners.

Emmes Group® names Germaine Gross Chief Commercial Officer of Emmes® Biopharma

[Emmes Group](https://www.theemmesgroup.com/)®, a leading specialty tech and AI-enabled global contract research organization (CRO), today announced the appointment of Germaine Gross to the role of Chief Commercial Officer,…

Essex Management Appoints David Loose as Chief Executive Officer

David Loose joined Essex Management as a partner in February 2009 and has played a pivotal role in the company’s growth. Starting as Vice President for Business Operations and Development, he later served as Chief Business Officer,…

Emmes adds new role as it looks to expand government footprint

Emmes**®**, part of Emmes Group**®**, a leading specialty tech and AI-enabled global contract research organization (CRO), today announced the appointment of Bryan Patterson to the newly created role of Senior Vice President, Government…

Novel stem cell therapy to treat central retinal vein occlusion

FDA Approves First Cellular Therapy to Treat Patients with Severe Aplastic Anemia

Essex Management Appoints David Loose as Chief Executive Officer

Emmes CEO on AI in clinical research

Navigating Funding Freezes and AI Frontiers

2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research